Literature DB >> 21461400

Regulatory T cells in HIV immunotherapy.

Bernard Jc Macatangay1, Charles R Rinaldo.   

Abstract

Significant research has been conducted on the role of regulatory T cells (Tregs) in HIV infection. To date, however, it is not clear whether Tregs play a detrimental role or a beneficial role in the pathogenesis of HIV infection. In fact, a number of immunotherapeutic strategies to control HIV infection have revealed a possible antagonistic role for Tregs. This necessitates investigating ways to counteract the suppressive function, such as through Treg depletion or blockade of specific Treg immunosuppressive mechanisms, without further increasing the cellular immune activation associated with chronic HIV infection. Simply applying Treg immunotherapeutic strategies used in diseases other than HIV may pose problems due to the complexity of HIV immunopathogenesis. Studies are therefore necessary to elucidate the different immunoregulatory networks in HIV infection in order to determine the specific cellular or molecular pathways that can be altered to boost the body's immune control of HIV.

Entities:  

Year:  2010        PMID: 21461400      PMCID: PMC3065023          DOI: 10.2217/hiv.10.51

Source DB:  PubMed          Journal:  HIV Ther        ISSN: 1758-4329


  84 in total

Review 1.  Regulatory T cells in HIV infection: pathogenic or protective participants in the immune response?

Authors:  Barbara Fazekas de St Groth; Alan L Landay
Journal:  AIDS       Date:  2008-03-30       Impact factor: 4.177

2.  CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques.

Authors:  Anna Hryniewicz; Adriano Boasso; Yvette Edghill-Smith; Monica Vaccari; Dietmar Fuchs; David Venzon; Janos Nacsa; Michael R Betts; Wen-Po Tsai; Jean-Michel Heraud; Brigitte Beer; Diann Blanset; Claire Chougnet; Israel Lowy; Gene M Shearer; Genoveffa Franchini
Journal:  Blood       Date:  2006-08-08       Impact factor: 22.113

3.  Immune exhaustion occurs concomitantly with immune activation and decrease in regulatory T cells in viremic chronically HIV-1-infected patients.

Authors:  Meenakshi Sachdeva; Margaret A Fischl; Rajendra Pahwa; Naresh Sachdeva; Savita Pahwa
Journal:  J Acquir Immune Defic Syndr       Date:  2010-08       Impact factor: 3.731

4.  Naturally anergic and suppressive CD25(+)CD4(+) T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation.

Authors:  Y Kuniyasu; T Takahashi; M Itoh; J Shimizu; G Toda; S Sakaguchi
Journal:  Int Immunol       Date:  2000-08       Impact factor: 4.823

5.  Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study.

Authors:  J A Kovacs; M Baseler; R J Dewar; S Vogel; R T Davey; J Falloon; M A Polis; R E Walker; R Stevens; N P Salzman; Lane H. Clifford
Journal:  N Engl J Med       Date:  1995-03-02       Impact factor: 91.245

6.  Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment.

Authors:  Yves Levy; Christine Lacabaratz; Laurence Weiss; Jean-Paul Viard; Cecile Goujard; Jean-Daniel Lelièvre; François Boué; Jean-Michel Molina; Christine Rouzioux; Véronique Avettand-Fénoêl; Thérèse Croughs; Stéphanie Beq; Rodolphe Thiébaut; Geneviève Chêne; Michel Morre; Jean-François Delfraissy
Journal:  J Clin Invest       Date:  2009-03-16       Impact factor: 14.808

7.  Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance.

Authors:  Xuefang Cao; Sheng F Cai; Todd A Fehniger; Jiling Song; Lynne I Collins; David R Piwnica-Worms; Timothy J Ley
Journal:  Immunity       Date:  2007-10-04       Impact factor: 31.745

8.  Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).

Authors:  Mary A Vogler; Hedy Teppler; Rebecca Gelman; Fred Valentine; Michael M Lederman; Roger J Pomerantz; Richard B Pollard; Deborah Weng Cherng; Charles J Gonzalez; Kathleen E Squires; Ian Frank; Donna Mildvan; Laura F Mahon; Barbara Schock
Journal:  J Acquir Immune Defic Syndr       Date:  2004-05-01       Impact factor: 3.731

9.  Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection.

Authors:  Valentina Cecchinato; Elzbieta Tryniszewska; Zhong Min Ma; Monica Vaccari; Adriano Boasso; Wen-Po Tsai; Constantinos Petrovas; Dietmar Fuchs; Jean-Michel Heraud; David Venzon; Gene M Shearer; Richard A Koup; Israel Lowy; Christopher J Miller; Genoveffa Franchini
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

10.  Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals.

Authors:  Nancy C Connolly; Theresa L Whiteside; Cara Wilson; Venkatswarlu Kondragunta; Charles R Rinaldo; Sharon A Riddler
Journal:  Clin Vaccine Immunol       Date:  2007-10-17
View more
  8 in total

1.  Altered phenotype of regulatory T cells associated with lack of human immunodeficiency virus (HIV)-1-specific suppressive function.

Authors:  C T Burton; S J Westrop; I Eccles-James; A Boasso; M R Nelson; M Bower; N Imami
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

2.  Programming T cell Killers for an HIV Cure: Teach the New Dogs New Tricks and Let the Sleeping Dogs Lie.

Authors:  Kellie N Smith; Robbie B Mailliard; Charles R Rinaldo
Journal:  For Immunopathol Dis Therap       Date:  2015

3.  Regulatory T cells: the ultimate HIV reservoir?

Authors:  Joseph Rocco; John W Mellors; Bernard Jc Macatangay
Journal:  J Virus Erad       Date:  2018-10-01

4.  Chronic morphine administration differentially modulates viral reservoirs in SIVmac251 infected rhesus macaque model.

Authors:  Arpan Acharya; Omalla A Olwenyi; Michellie Thurman; Kabita Pandey; Brenda M Morsey; Benjamin Lamberty; Natasha Ferguson; Shannon Callen; Qiu Fang; Shilpa J Buch; Howard S Fox; Siddappa N Byrareddy
Journal:  J Virol       Date:  2020-12-16       Impact factor: 5.103

5.  Professional antigen presenting cells in human herpesvirus 8 infection.

Authors:  Emilee R Knowlton; Lauren M Lepone; Jun Li; Giovanna Rappocciolo; Frank J Jenkins; Charles R Rinaldo
Journal:  Front Immunol       Date:  2013-01-21       Impact factor: 7.561

Review 6.  HIV-1 Trans Infection of CD4(+) T Cells by Professional Antigen Presenting Cells.

Authors:  Charles R Rinaldo
Journal:  Scientifica (Cairo)       Date:  2013-05-07

7.  Regulatory T cells expanded from HIV-1-infected individuals maintain phenotype, TCR repertoire and suppressive capacity.

Authors:  Mathieu Angin; Paul L Klarenbeek; Melanie King; Siddhartha M Sharma; Eshia S Moodley; Ashley Rezai; Alicja Piechocka-Trocha; Ildiko Toth; Andrew T Chan; Philip J Goulder; Thumbi Ndung'u; Douglas S Kwon; Marylyn M Addo
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

Review 8.  The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and Outlook.

Authors:  Hager Mohamed; Vandana Miller; Stephen R Jennings; Brian Wigdahl; Fred C Krebs
Journal:  J Immunol Res       Date:  2020-05-25       Impact factor: 4.818

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.